Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cadex Genomics Corp. is currently addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio involves 1 distinct examiner and 1 distinct art unit. This indicates a point of contact within the patent office for the company's current pending matters.
The busiest examiner, BUCHANAN, BAILEY CHEYENNE, is responsible for 1 pending office action. As the portfolio only has a total of 1 pending office action, this examiner is the sole individual currently reviewing the company's active office action responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786969 | Multiplexed Assay Using Differential Fragment Size to Identify Cancer Specific Cell-Free DNA | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786969 | Multiplexed Assay Using Differential Fragment Size to Identify Cancer Specific Cell-Free DNA | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786969 | Multiplexed Assay Using Differential Fragment Size to Identify Cancer Specific Cell-Free DNA | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103§112 | Non-Final OA | — | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCadex Genomics Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bailey Cheyenne Buchanan has the most, with 1 of Cadex Genomics Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
